Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

men. The primary endpoint of the study is PFS. This global study, conducted by Janssen outside the US, is recruiting and Janssen plans to enroll 280 patients.
  • SHINE (MCL3002): Phase III study of ibrutinib in combination with bendamustine and rituximab in elderly patients with newly diagnosed MCL. This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in patients 65 years or older with newly diagnosed MCL. The primary endpoint of the study is PFS. This global study, conducted by Janssen, is recruiting and Janssen plans to enroll 520 patients.
  • MCL4001: A multicenter, open label Expanded Access Program (EAP) for ibrutinib as a monotherapy in relapsed/refractory (R/R) MCL patients has been initiated in the US by Janssen. EAPs are clinical studies allowed under certain circumstances by the FDA. They are designed to provide a mechanism for access to an investigational drug to treat patients with a serious or immediately life-threatening diseases or conditions until the time of an anticipated U.S. marketing approval. Further information about this program can be found on www.clinicaltrials.gov.
  • DLBCL

  • PCYC-1106: Phase II study of ibrutinib in patients with relapsed or refractory DLBCL. This trial is a multicenter, open-label study designed to assess the activity of ibrutinib in two genetically distinct subtypes of DLBCL, the activated B-cell (ABC) subtype and the germinal center B-cell (GCB) subtype. This trial is active in several US sites and Pharmacyclics has enrolled 70 patients with updated results most recently published at EHA in June 2013. In July a new cohort with ibrutinib dosed at 840mg in patients with non-GCB subtype DLBCL was initiated. This cohort will increase the enrollment target for this study to 125 patients.
  • DBL1002: Phase Ib dose escalating stu
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... Jan. 23, 2015  Now available for sale, The Armor1 ... that prevents ankle sprains by cushioning the ankle from ... securely around the outside of any shoe type and ... while still offering protection against sprains. With customers in ...
    (Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
    (Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
    Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
    ... Mass., Dec. 1, 2011 Hologic, Inc. (NASDAQ: ... and Chief Financial Officer, will be presenting at the Nasdaq ... 2011, at 11:15am (GMT). Interested parties are invited ... presentation on the investor section of Hologic,s website at ...
    ... Dec. 1, 2011 Reportlinker.com announces ... is available in its catalogue: ... and Services Market 2011-2021 ... What are the commercial prospects for ...
    Cached Medicine Technology:Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 13
    (Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
    (Date:1/22/2015)... Mass. (PRWEB) January 22, 2015 EBSCO ... (AMA) are expanding their relationship in an effort to ... around the world. While EBSCO has long made AMA journals ... a sales agent for The JAMA Network. , ...
    (Date:1/22/2015)... 2015 Compare-autoinsurance.org has released a new blog post ... auto insurance policy . , Some types of vehicles ... check the newly released blog post to see if their vehicle ... damaged vehicles are some of the cars that cannot be covered ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 State Forestry ... data management system with support from GEOSYSTEMS, a dedicated ... new solution will leverage Hexagon Geospatial’s ERDAS APOLLO ... data as well as point clouds and documents. This ...
    Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
    ... a common malady that many suffer from, it often breeds ... out effort to overcome it those struggling with this malady ... notably notorious in causing bad breath//. In the absence of ... gums, and mouth rinses are usually resorted to. ...
    ... the gray matter has offered an insight into a trait ... – SELFISHNESS//. Bewildering all the same, why are some people ... believe in being the epitome of selflessness! ,Scientists ... the front of the brain, termed as the dorsolateral prefrontal ...
    ... mother underwent sheer misery, caught between the devil and the ... was in dire need of emergency mental// healthcare. The patient, ... a year, before any form of counseling was attempted. ... a history of two suicide attempts. According to the ...
    ... kid who died due to kidney failure last month was ... that has caused a// countrywide outbreak of food poisoning. ... died on Sept. 20, is the second confirmed fatality of ... in the United States and one person in Canada,' said ...
    ... issued Global Air Quality Guidelines on Thursday so as to ... each year with most of the deaths occurring in developing ... air quality in the cities. A statement issued by the ... could be saved every year by bringing down the PM10 ...
    ... Nearly three out of every hundred pregnant women in Andhra Pradesh ... infants. The Andhra Pradesh State AIDS// Control Society (APSACS) has ... The vision for this group is clear - the society strives ... ,A pioneering effort of its kind in the country, the ...
    Cached Medicine News:
    ... The Hgb Pro Professional Hemoglobin Testing ... and single-use test strips, used in measuring ... blood. The Hgb Pro provides the precision, ... require., ,The Hgb Pro Professional Hemoglobin Testing ...
    ... is a fully automated analyzer that requires ... time by the operator. The Variant II ... tubes. It reads the bar code, samples ... the specimen into the chromatographic station for ...
    ... The Advia 70 hematology system ... 5-part differential. Designed for speed ... analyzer combines cost-effectiveness with impressive ... suitable either on its own ...
    AcT 5diff OV enables low-volume labs to advance to 5-part differential analysis at an affordable price. This analyzer delivers accurate test results and a user-friendly software interface in a compac...
    Medicine Products: